COVID-19 2024 fall guide: Everything Canadians should know about new Moderna vaccine, current variants and more
NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in the fall of 2024." The organization recommends a six-month interval between COVID vaccines, "with a minimum of three months from the last dose."
Moderna Stock Jumps on Canadian Government's Approval of Updated COVID-19 Vaccine
Key Takeaways Moderna shares surged Tuesday after Canadian regulators approved the biotech firm’s updated COVID-19 vaccine.Moderna's Spikevax KP.2 targets the KP.2 variant of the virus.The U.S. Food and Drug Administration has also approved the shot,
Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
SPIKEVAX® is the first updated COVID-19 vaccine authorized in Canada for 2024-2025, offering a timely solution to help protect Canadians
Health Canada approves updated Novavax COVID-19 vaccine
According to a Thursday update on the government’s vaccine portal, Health Canada will replace the older version of the protein-based vaccine, Nuvaxovid XBB.1.5. The new version will include an update to the antigen composition targeting the JN.1 variant.
Moderna Gets Canada Approval for Updated Covid-19 Vaccine
The biotechnology company on Tuesday said that Health Canada authorized the vaccine targeting the KP.2 Covid-19 variant of Sars-Cov-2. Moderna will begin delivery of updated doses to the Public Health Agency of Canada,
Be warned: Check your insurance before getting a COVID-19 vaccine this year
For those who are uninsured or under-insured, CDPH will have vaccine at its three CDPH Immunization Clinics. Walk-ins are ...
Latest COVID variant, XEC, has spread to half of US states, reports say
The latest strain of the COVID-19 virus, XEC, is circulating across the country. The new variant has been reported in at ...
Moderna: Still Bullish View
Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...
Down More Than 50%, Is It Time to Buy Moderna Stock as the Biotech Charts a New Post-COVID Path?
With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...
Medscape1d
EU OKs Meningococcal Disease Vaccine
The EMA has approved Penbraya for protection against invasive meningococcal disease and an update of the composition of two ...
What's Going On With Moderna Shares Tuesday?
Moderna shares are moving higher on Tuesday after the company announced that Health Canada approved its updated COVID-19 ...
Moderna lays out plan to slice research and development spending
Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending ...
Moderna stock plunges nearly 20% as company reports poor COVID-19 vaccine sales and cuts to research plans
Moderna (NYSE: MRNA) stock plunged Thursday on news it will be slashing its research and development budget by about 20% over ...